Study to Compare Exposure of TA Following Administration of Either FX006 or TAcs in Patients With Bilateral Knee OA
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03378076|
Recruitment Status : Completed
First Posted : December 19, 2017
Results First Posted : May 1, 2019
Last Update Posted : December 5, 2019
|Condition or disease||Intervention/treatment||Phase|
|Bilateral Knee Osteoarthritis||Drug: FX006 32 mg Drug: TAcs 40 mg||Phase 2|
This is a randomized, open label, parallel group study that will be conducted in male and female patients ≥ 40 years of age with bilateral knee OA.
Approximately 24 patients will be randomized to one of two treatment groups (1:1) and treated with IA injections to both knees of either:
- extended-release FX006 64 mg total dose (approximately 12 patients) or
- immediate-release TAcs 80 mg total dose (approximately 12 patients) Each patient will be screened to confirm the diagnosis of OA and eligibility based on the inclusion/exclusion requirements and will be randomized to treatment on Day 1. Following screening, pharmacokinetics (PK) and safety will be evaluated at 6 out-patient visits scheduled on Study Days 1 [calendar day of injection], 2, 8, 15, 29, and 43.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||24 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Randomized, Open-label, Parallel Group Study in Patients With Bilateral Knee Osteoarthritis Comparing the Systemic Exposure of Triamcinolone Acetonide Following Administration Into Both Knees of Either Extended-release FX006 or Immediate-release TAcs (Triamcinolone Acetonide Suspension)|
|Actual Study Start Date :||December 6, 2017|
|Actual Primary Completion Date :||March 14, 2018|
|Actual Study Completion Date :||March 14, 2018|
Experimental: FX006 32 mg
Two intra-articular (IA) injections of FX006 32 mg (total dose of 64 mg)
Drug: FX006 32 mg
Drug: Extended-release 32 mg FX006 IA injection into each knee (total 64 mg dose)
Other Name: Zilretta
Active Comparator: TAcs 40 mg
Two intra-articular (IA) injections of TAcs 40 mg (total dose of 80 mg)
Drug: TAcs 40 mg
Drug: Immediate-release 40mg TAcs IA injection into each knee (total 80 mg dose)
- Measure the Concentration of Triamcinolone Acetonide (TA) in Blood Plasma [ Time Frame: 43 days ]
Plasma drug concentrations (pg/mL) by Time Point across FX006 and TAcs treatment arms in plasma.
For the PK analysis and individual concentration vs. time plots, a concentration that is BLOQ is assigned a value of zero if it occurs in a profile before the first measurable concentration. If a BLOQ value occurs after a measurable concentration in a profile and is followed by a value above the lower limit of quantification, then the BLOQ is treated as missing data. If a BLOQ value occurs at the end of the collection interval (after the last quantifiable concentration) it is set to zero. If two BLOQ values occur in succession after Cmax, the profile is deemed to have terminated at the first BLOQ value and any subsequent concentrations are set to zero for PK calculations
- Incidence of Treatment Emergent Adverse Events [ Time Frame: 43 days ]
Safety analyses were conducted using the safety population.
Analyses of adverse events will be performed for those events that are considered treatment emergent, where treatment emergent is defined as any adverse event with onset after the administration of study medication in the first knee through the end of the study or any event that was present at baseline but worsened in intensity through the end of the study. Severity of Adverse events were graded by the Principal Investigator using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. The grading went from Grade 1 (Mild) to Grade 5 (Death related to AE).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03378076
|United States, California|
|LA Biomed at Harbor-UCLA Medical Center|
|Torrance, California, United States, 90509|
|United States, New York|
|Rochester Clinical Research|
|Rochester, New York, United States, 14609|
|United States, Pennsylvania|
|Altoona Center for Clinical Research|
|Duncansville, Pennsylvania, United States, 16635|
|Study Director:||Scott Kelley, MD||Flexion Therapeutics, Inc.|